Nanotrap® Microbiome B Particles Enable Capture of Candida auris, Cryptosporidium parvum, and Giardia lamblia from Wastewater
APPLICATION NOTE SKU 65XXX
Key Advantages
> Rapidly capture and concentrate pathogenic yeast and parasites, without filtration or centrifugation.
> Single sample processing method can be used to identify multiple microbes of interest.
> Workflow can be automated on a KingFisher™ System.
> Methods are scalable for large volume sample processing.
Introduction
Wastewater-based epidemiology is used to identify and monitor pathogens in communities. It experienced a massive growth and was widely heralded during the SARS-CoV-2 pandemic. This interest has expanded to other pathogens, including eukaryotes such as parasitic organisms and multi-drug resistant yeast. The CDC has identified several of these type of pathogens as emerging threats including Candida auris and several infection-causing parasitic organisms.
Nanotrap Microbiome A Particles are used in wastewater testing across the country to monitor SARS-CoV-2 in communities. More recently, the Nanotrap A Microbiome Particles and Nanotrap B Microbiome Particles have allowed detection of emerging diseases including mpox virus and Clostridioides difficile, both of which are included on the CDC emerging threats list.
Using the Nanotrap Microbiome B Particles, a new, automation-friendly method has been developed to enable improved detection of eukaryotic pathogens (such as C. auris, Cryptosporidium parvum, and Giardia lamblia) in wastewater samples.
In this application note, we show that Nanotrap Microbiome B Particles can: 1) capture and concentrate multiple eukaryotic organisms from wastewater samples; 2) improve detection of those organisms as compared to an alternative method; and 3) are compatible with multiplex qPCR assays on the Bio-Rad CFX96.
